Overview

Pharmacokinetic Study of QL2107 Versus Keytruda for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Status:
NOT_YET_RECRUITING

Trial end date:
2027-05-31

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to demonstrate Pharmacokinetic similarity in exposure after the initial dose and at steady state of QL2107 compared with Keytruda.

Phase:

PHASE3

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

pembrolizumab